» Articles » PMID: 11480221

Animal Models of Tardive Dyskinesia--a Review

Overview
Specialties Pharmacology
Physiology
Date 2001 Aug 2
PMID 11480221
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Tardive dyskinesia is a serious motor side effect of long term neuroleptic therapy, with an unknown pathophysiological basis. The leading hypothesis of the pathophysiology of tardive dyskinesia includes dopamine receptor supersensitivity, GABAergic hypofunction, excitotoxicity and oxidative stress. Many preclinical models have been developed to identify the underlying pathological processes of tardive dyskinesia, but none has yet produced a parsimonious results. A wide range of animal models, viz. Homologous, analogous and correlational models have been developed to explore the pathophysiology of tardive dyskinesia. Vacuous chewing movements in rodents induced by chronic neuroleptic treatment is the most frequently employed model. As the existing models suffer from several phenomenological and methodological problems, development of new models, highly predictive of pathological basis of tardive dyskinesia can accelerate tardive dyskinesia research for the better understanding of the pathophysiological processes underlying the syndrome and for the discovery of new therapeutic targets for the treatment of tardive dyskinesia.

Citing Articles

Levosulpiride-induced Movement Disorders.

Choudhury S, Chatterjee K, Singh R, Shubham S, Trivedi S, Chatterjee S J Pharmacol Pharmacother. 2018; 8(4):177-181.

PMID: 29472751 PMC: 5820749. DOI: 10.4103/jpp.JPP_32_17.


Experimental treatment of antipsychotic-induced movement disorders.

Shireen E J Exp Pharmacol. 2016; 8:1-10.

PMID: 27540314 PMC: 4982503. DOI: 10.2147/JEP.S63553.


α-Lipoic acid interaction with dopamine D2 receptor-dependent activation of the Akt/GSK-3β signaling pathway induced by antipsychotics: potential relevance for the treatment of schizophrenia.

Deslauriers J, Desmarais C, Sarret P, Grignon S J Mol Neurosci. 2012; 50(1):134-45.

PMID: 22975849 DOI: 10.1007/s12031-012-9884-4.


D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways.

Kovoor A, Seyffarth P, Ebert J, Barghshoon S, Chen C, Schwarz S J Neurosci. 2005; 25(8):2157-65.

PMID: 15728856 PMC: 6726050. DOI: 10.1523/JNEUROSCI.2840-04.2005.